The frequencies of cutaneous irAEs in metastatic melanoma patients treated with ipilimumab or anti-PD-1 antibodies are comparable, although anti-PD-1 therapy usually elicits milder reactions, and they have been associated with improved clinical responses and survival [99]. The gene discussed is PDCD1; the disease is metastatic melanoma.